MEDIUM confidence: 100% data completeness, but the composite (57) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net insider -$128K over 180 days (0 open-market buys, 2 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $12.6B— | $13.4B+6.0% | $14.3B+6.6% | $15.8B+10.8% | $17.4B+9.7% |
| EPS (dil.) | $11.82— | $9.14-22.7% | $10.23+11.9% | $16.82+64.4% | $23.10+37.3% |
| Free Cash Flow | $28M— | $262M+834.6% | $525M+100.3% | $1.1B+114.1% | $849M-24.4% |
| Gross Margin | 88.7% | 89.0%+0.3pp | 89.3%+0.3pp | 90.0%+0.7pp | 90.4%+0.5pp |
| Operating Margin | 10.8% | 7.5%-3.3pp | 8.2%+0.7pp | 10.6%+2.4pp | 11.5%+0.9pp |
| Net Margin | 7.8% | 5.0%-2.8pp | 5.0%-0.0pp | 7.2%+2.2pp | 8.6%+1.4pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 5.1%/yr (revenue basis).
Base free cash flow $832M (avg FY2023–FY2025; latest year $849M) · equity value $10.3B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Avg target $189 (last qtr, 11 analysts) → $197 (last mo, 8) (+3.8%).
Buy-rated share 40% → 35% over ~3 months (-5pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $5.94 | $5.98 | +0.7% |
| Apr 2026 | $5.41 | $5.62 | +3.9% |
| Feb 2026 | $5.92 | $5.88 | -0.7% |
| Oct 2025 | $4.66 | $5.69 | +22.1% |
| Jul 2025 | $4.92 | $5.35 | +8.7% |
| Apr 2025 | $4.35 | $4.84 | +11.3% |
| Feb 2025 | $4.21 | $4.92 | +16.9% |
| Oct 2024 | $3.65 | $3.71 | +1.6% |
The QScore of 57 for Universal Health Services indicates a neutral outlook, with the stock scoring high on value and profitability, driven by a low P/E of 6.9 and an ROE of 20.7%. However, growth and momentum scores are lower, due to a decline in free cash flow growth and a negative 12-month return of -2.8%. The long-term and short-term scores are relatively aligned, with only a 2-point difference, suggesting a consistent view across different time horizons. The stock's risk score is relatively high, driven by a beta of 1.1 and elevated 60-day volatility of 33.5%.